Kenacort

NDA 11283, held by Delcor Asset Corp. Triamcinolone.

As of Nov 13, 2026, NDA 11283 (Kenacort), held by Delcor Asset Corp, was first approved by FDA on Jan 14, 1958, with 11 approved supplements and 0 published complete response letters.

First approved: Jan 14, 1958
Review: Standard
Supplements approved: 11
Complete response letters: 0

Approvals and New Uses

The original application and every efficacy supplement, newest first; all 12 submissions below

Date	Submission	Status	Documents
Jan 14, 1958	Original applicationNew formulation or manufacturer · Standard review	Approved	None posted

Products

4 strengths and forms


Kenacort1MG · tablet;oral	Triamcinolone	Discontinued
Kenacort4MG · tablet;oral	Triamcinolone	Discontinued
Kenacort2MG · tablet;oral	Triamcinolone	Discontinued
Kenacort8MG · tablet;oral	Triamcinolone	Discontinued

All 12 submissions, including labeling and manufacturing supplements


Dec 7, 2007	Supplement 34Labeling	Approved	None posted
Dec 7, 2007	Supplement 35Labeling	Approved	None posted
Dec 7, 2007	Supplement 39Labeling	Approved	None posted
Dec 7, 2007	Supplement 42Labeling	Approved	None posted
Sep 7, 1993	Supplement 44Labeling	Approved	None posted
Nov 30, 1987	Supplement 43Manufacturing · Standard review	Approved	None posted
Aug 21, 1979	Supplement 40Manufacturing · Standard review	Approved	None posted
Jul 17, 1979	Supplement 33Labeling	Approved	None posted
Jul 17, 1979	Supplement 37Manufacturing · Standard review	Approved	None posted
Jun 4, 1979	Supplement 38Labeling	Approved	None posted
Jul 19, 1968	Supplement 3	Approved	None posted
Jan 14, 1958	Original applicationNew formulation or manufacturer · Standard review	Approved	None posted

Identifiers

Application: NDA 11283
Drugs@FDA: Overview at FDA
Company: Delcor Asset Corp.

Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters